(Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | (Q6)Jun 30, 2022 | (Q3)Mar 31, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Turnover | -29.18%1.9B | -21.71%998.15M | -31.39%6.45B | -25.86%5.19B | -35.11%2.68B | -42.31%1.27B | 9.46%9.39B | 17.96%7B | 4.76%4.13B | --2.21B |
Operating income | -29.18%1.9B | -31.39%6.45B | -35.11%2.68B | 9.46%9.39B | 4.76%4.13B | |||||
Cost of sales | 29.21%-1.87B | ---- | 31.15%-6.34B | ---- | 34.78%-2.64B | ---- | -10.10%-9.2B | ---- | -4.34%-4.04B | ---- |
Operating expenses | 29.21%-1.87B | 31.15%-6.34B | 34.78%-2.64B | -10.10%-9.2B | -4.34%-4.04B | |||||
Gross profit | -27.76%28.62M | -42.79%109.82M | -51.49%39.62M | -14.46%191.96M | 31.07%81.68M | |||||
Selling expenses | 61.97%-2.16M | ---- | 39.57%-5.39M | ---- | -68.14%-5.68M | ---- | 34.29%-8.91M | ---- | 5.51%-3.38M | ---- |
Administrative expenses | 47.69%-47.17M | ---- | 12.65%-156.91M | ---- | 2.35%-90.18M | ---- | -3.29%-179.64M | ---- | 7.56%-92.35M | ---- |
Research and development expenses | 10.05%-23.8M | ---- | 23.30%-57.11M | ---- | 29.34%-26.46M | ---- | 30.00%-74.45M | ---- | 40.27%-37.45M | ---- |
Impairment and provision | 97.20%-1.42M | ---- | -64.66%-138.71M | ---- | -250.88%-50.74M | ---- | -399.92%-84.24M | ---- | ---14.46M | ---- |
-Impairment of property, machinery and equipment | ---- | ---- | -31.84%-4.88M | ---- | ---- | ---- | 69.58%-3.7M | ---- | ---- | ---- |
-Other impairment is provision | 97.20%-1.42M | ---- | -66.17%-133.82M | ---- | -250.88%-50.74M | ---- | -1,621.18%-80.53M | ---- | ---14.46M | ---- |
Operating interest expense | ---- | ---- | -104.88%-60.6M | ---- | ---- | ---- | -233.20%-29.58M | ---- | -84.60%-7.25M | ---- |
Special items of operating profit | -67.57%43.05M | ---- | 73.05%229.51M | ---- | 109.02%132.73M | ---- | -20.32%132.63M | ---- | -16.95%63.5M | ---- |
Operating profit | -302.79%-2.88M | -51.97%-79.39M | 92.63%-716K | -173.29%-52.24M | 69.00%-9.71M | |||||
Financing cost | -28.73%-30.32M | ---- | ---- | ---- | ---23.55M | ---- | ---- | ---- | ---- | ---- |
Share of profits of associates | 308.94%6.78M | ---- | 88.85%-344K | ---- | 20.99%-3.25M | ---- | -176.19%-3.09M | ---- | -4,178.13%-4.11M | ---- |
Share of profit from joint venture company | -38.39%-2.89M | ---- | -362.62%-20.18M | ---- | 59.45%-2.09M | ---- | ---4.36M | ---- | ---5.15M | ---- |
Earning before tax | 0.97%-29.31M | -67.39%-99.9M | -56.06%-29.6M | -185.07%-59.68M | 39.62%-18.97M | |||||
Tax | 88.48%-2.33M | ---- | -67.61%-20.87M | ---- | -316.77%-20.23M | ---- | 9.35%-12.45M | ---- | -257.37%-4.86M | ---- |
After-tax profit from continuing operations | 36.50%-31.64M | -67.43%-120.77M | -109.19%-49.84M | -227.85%-72.14M | 15.91%-23.82M | |||||
Earning after tax | 36.50%-31.64M | 60.99%-20.41M | -67.43%-120.77M | -82.52%-70.2M | -109.19%-49.84M | -178.27%-52.32M | -227.85%-72.14M | -470.99%-38.46M | 15.91%-23.82M | -18.8M |
Minority profit | -135.91%-65K | ---- | -232.14%-93K | ---- | 520.93%181K | ---- | -129.47%-28K | ---- | 70.34%-43K | ---- |
Profit attributable to shareholders | 36.86%-31.58M | -67.36%-120.68M | -110.33%-50.02M | -228.01%-72.11M | 15.63%-23.78M | |||||
Basic earnings per share | 33.33%-0.004 | -67.03%-0.0152 | -100.00%-0.006 | -30.00%-0.0091 | 0.00%-0.003 | |||||
Diluted earnings per share | 33.33%-0.004 | -67.03%-0.0152 | -100.00%-0.006 | -30.00%-0.0091 | -0.003 | |||||
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS |
Audit Opinions | -- | -- | Unqualified Opinion | -- | -- | -- | Unqualified Opinion | -- | -- | -- |
Auditor | -- | -- | Deloitte & Touche Tohmatsu Certified Public Accountants | -- | -- | -- | Deloitte & Touche Tohmatsu Certified Public Accountants | -- | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
No Data